Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: A randomized controlled trial in Burkina Faso

Journal of Infectious Diseases

Volumn 211, Issue 5, 2015, Pages 689-697

  Coulibaly, Boubacar ^a   Pritsch, Michael ^c,d,e   Bountogo, Mamadou ^a   Meissner, Peter E ^f   Nebié, Eric ^a   Klose, Christina ^g   Kieser, Meinhard ^g   Berens Riha, Nicole ^c   Wieser, Andreas ^c,d,e   Sirima, Sodiomon B ^b   Breitkreutz, Jörg ^h   Schirmer, R Heiner ^g   Sié, Ali ^a   Mockenhaupt, Frank P ⁱ   Drakeley, Chris ^j   Bousema, Teun ^j,k   Müller, Olaf ^g  

^a CENTRE DE RECHERCHE EN SANTÉ DE NOUNA   (Burkina Faso)

^b Centre National de Recherche et de la Formation sur Paludisme   (Burkina Faso)

^c Limbach Laboratory   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Partner Site Heidelberg   (Germany)

^f UNIVERSITY OF ULM   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Africa; Gametocytes; Malaria; Methylene blue

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; HEMOGLOBIN; METHYLENE BLUE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE;

ARTICLE; BURKINA FASO; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE INFECTION; FEMALE; FEVER; GAMETOCYTE; GASTROINTESTINAL INFECTION; HEMOLYSIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MICROBIOLOGICAL PARAMETERS; MICROSCOPY; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PARASITE DENSITY; PARASITE PREVALENCE; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; STOMACH PAIN; TREATMENT DURATION; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; PATHOLOGY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; BURKINA FASO; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; METHYLENE BLUE; MICROSCOPY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84929702233     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu540     Document Type: Article

References (43)

1. Nosten F, Brasseur P. Combination therapy for malaria-the way forward? Drugs 2002;62:1315-29.
2. Zwang J, Olliaro P, Barennes H, et al. Efficacy of artesunate-amodia-quine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J 2009;8:203.
3. Targett G, Drakeley C, Jawara M, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis 2011;183:1254-9.
4. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013;207:1637-45.
5. Schirmer H, Coulibaly B, Stich A, et al. Methylene blue as an antima-larial agent-past and future. Redox Report 2003;8:272-6.
6. Guttmann P, Ehrlich P. Ueber die Wirkung des Methylenblau bei Malaria. Berliner Klin Wochenschr 1891;39:953-6.
7. Ehrlich P. Chemotherapeutics: scientific principles, methods, and results. Lancet 1913; ii: 445-51.
8. Walter-Sack I, Rengelshausen J, Oberwittler H, et al. High absolute bio-availability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol 2009;65:179-89.
9. Peter C, Hongwan D, Küpfer A. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000;56:247-50.
10. Mandi G, Witte S, Meissner P, et al. Safety of the combination of chlo-roquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health 2005;10:32-8.
11. Meissner P, Mandi G, Witte S, et al. Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso. Malaria J 2005;4:46.
12. Meissner P, Mandi G, Coulibaly B, et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloro-quine. Malaria J 2006;5:84.
13. Zoungrana A, Coulibaly B, Sié A, et al. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated fal-ciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One 2008;3:e1630.
14. Bountogo M, Zoungrana A, Coulibaly B, et al. Short communication: efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health 2010;15:713-7.
15. Müller O, Mockenhaupt FP, Marks B, et al. Haemolysis risk in methy-lene blue treatment of G6PD sufficient and G6PD deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidemiol Drug Saf 2013;22:376-85.
16. Coulibaly B, Zoungrana A, Mockenhaupt F, et al. Strong gametocytoci-dal effect of methylene blue-based combination therapy against falcip-arum malaria: a randomised controlled trial. PLoS One 2009;4:e5318.
17. Akoachere M, Buchholz K, Fischer E, et al. In vitro assessment of meth-ylene blue on chloroquine-sensitive and -resistant Plasmodium falcipa-rum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother 2005;49:4592-7.
18. Müller O, Yé M, Louis V, et al. Malaria in sub-Saharan Africa. Lancet 2009;373:122.
19. Sié A, Louis V, Gbangou A, et al. The Health and Demographic Surveillance System (HDSS) in Nouna, Burkina Faso, 1993-2007. Glob Health Action 2010;3:5284.
20. Müller O, Becher H, Baltussen A, et al. Effect of zinc supplementation on malaria and other causes of morbidity in West African children: randomized double-blind placebo-controlled trial. BMJ 2001;322:1567-72.
21. Hammer GP, Somé F, Müller O, et al. Pattern of cause-specific childhood mortality in a malaria endemic area of Burkina Faso. Malar J 2006;5:47.
22. Tipke M, Louis V, Yé M, et al. Access to malaria treatment in young children of rural Burkina Faso. Malar J 2009;8:266.
23. De Allegri M, Louis V, Tiendrébeogo J, et al. Moving towards universal coverage with malaria control interventions: achievements and challenges in rural Burkina Faso. Int J Health Plann Manage 2013;28:102-21.
24. World Health Organization. Assessment and monitoring of antimalar-ial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, 2003. http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/. Accessed 11 October 2014.
25. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland: World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf. Accessed 30 December 2010.
26. Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs)- A novel solid dosage form for paediatric use. Eur J Pharm Biopharm 2011;78:462.
27. World Health Organization. Recommended genotyping procedures (RGPs) to identify parasite populations. Amsterdam, the Netherlands: Medicines for Malaria Venture and World Health Organization, 2007.
28. World Health Organization. Consultation on technical and operational recommendations for clinical laboratory testing harmonization and standardization. Geneva, Switzerland: World Health Organization, 2008.
29. Pritsch M, Wieser A, Soederstroem V, et al. Stability of gametocyte-specific Pfs25-mRNA in dried blood spots on filter paper subjected to different storing conditions. Malar J 2012;11:138.
30. Beshir KB, Sutherland CJ, Sawa P, et al. Residual Plasmodium falcipa-rum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis 2013;208:2017-24.
31. Borrmann S, Sasi P, Mwai L, et al. Declining responsiveness of Plasmo-dium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 2011;6:e0026005.
32. Eziefula AC, Bousema T, Yeung S, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomized, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 2014;14:130-9.
33. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013;13:175-81.
34. Luzzatto L. The rise and fall of the antimarial Lapdap: a lesson in pharmcogenetics. Lancet 2010;376:739-41.
35. Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. In: Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization, 2014.
36. Sawa P, Shelkalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013;207:1637-45.
37. Bousema JT, Schneider P, Gouagna LC, et al. Moderate effect of artemi-sinin-based combination therapy on transmission of Plasmodium fal-ciparum. J Infect Dis 2006;193:151-9.
38. Bousema T, Drakeley C. Review: epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011;24:377-410.
39. Delver MJ, Ruecker A, Straschil U, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother 2013;57:3268-74.
40. Day KP, Hayward RE, Dyer M. The biology of Plasmodium falciparum transmission stages. Parasitol 1998;116(suppl):S95-109.
41. Spomer N, Klingmann V, Stoltenberg I, et al. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child 2012;97:283.
42. Klingmann V, Spomer N, Lerch C, et al. Favourable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and pre-school children. J Pediatr 2013;163:1728-32.
43. World Health Organization. Report of the informal expert meeting on dosage forms of medicines for children. 17th Meeting of Expert Committee on Selection and Use of Essential Medicines, 15-16 December 2008. Geneva, Switzerland: World Health Organization, 2008. http://www.who.int/selection-medicines/committees/expert/17/application/paediatric/Dosage-form-reportDEC2008.pdf.